FIELD: medicine.
SUBSTANCE: described oil solution for injection to patient is characterised by the fact that it includes 25-200 mg/ml of the first component which is ethonogestrel ether and 50-400 mg/ml of the second component which the fatty acid ether with chain length within C6 to C12 and 7-alpha-methyl-19-nortestosterone, where progesterone ether and androgen ether are dissolved in ethylundecanoate. Besides, related introduction device is described.
EFFECT: high level of predisposition to treatment implying infrequent painless introduction without by-effects and local reactions.
2 cl, 2 tbl, 6 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF NOVEL ETHONOGESTREL ESTERS | 2003 |
|
RU2322986C2 |
| NEW ESTERS OF ETHONOGESTREL | 2003 |
|
RU2325910C2 |
| COMPOUND (α)-7-METHYL-17-[(1-OXOUNDECYL)OXY]-ESTR-4-ENE-3-ONE, PHARMACEUTICAL COMPOSITION, SET FOR MALE CONTRACEPTION | 1999 |
|
RU2216546C2 |
| STEROIDS WITH MIXED ANDROGENIC AND PROGESTAGENIC PROFILE | 2004 |
|
RU2357972C2 |
| METHOD AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE LEVELS OF TESTOSTERONE IN SERUM | 2004 |
|
RU2354381C2 |
| COMPOSITION COMPRISING TESTOSTERONE UNDECANOATE AND CASTOR OIL | 2000 |
|
RU2246296C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| STABLE PHARMACEUTICAL COMPOSITION CONTAINING TESTOSTERONE UNDECANOATE | 2019 |
|
RU2777534C1 |
| OESTROGEN RECEPTOR LIGANDS AND METHODS OF USING THEM | 2010 |
|
RU2543339C2 |
| COMPOUNDS, SET, ANDROGENIC COMPOSITION | 2000 |
|
RU2242479C2 |
